Stocks making the biggest moves premarket: Haemonetics, Broadcom, Lululemon, Wolfspeed & more

Premarket moves were mixed: Wolfspeed rose more than 15% after securing a conditional $1.5 billion Defense Department loan, while Haemonetics gained 8% on CSL’s planned U.S. rollout of its plasmapheresis platform by end-2027. TSMC reported third-quarter revenue of $16.03 billion, up 54.6% year over year and above expectations, but shares fell about 1%; Levi Strauss slipped nearly 3% after revenue of $1.61 billion slightly missed expectations and its sales outlook weakened. Applied Digital rose 1% as fiscal first-quarter revenue climbed 322% to nearly $342 million, while Broadcom and Lululemon traded lower.

Analysis

The clearest signal is capital allocation and execution risk, not a uniform read-through from the headline moves. For Broadcom (AVGO), financing linked to an OpenAI chip program could support demand, but if Broadcom is providing or backstopping material financing, it may shift risk from product margins toward customer credit, working capital, and concentration. The borrower, recourse, and repayment terms matter more than the headline amount; do not price this as booked revenue yet.

Wolfspeed (WOLF) gets potential liquidity runway, but conditionality and warrants mean the rally may discount funding before milestones are met and dilution is known. Treat it as a financing event, not proof of a durable earnings recovery. Applied Digital (APLD) has a two-sided AI signal: a hyperscaler's self-build validates power and site demand, but may also compete with third-party capacity. Contracted economics, power availability, and project funding determine which effect dominates.

Haemonetics (HAE) has a multi-year adoption catalyst, but rollout timing and customer concentration limit near-term certainty. TSM's revenue strength is supportive, not a substitute for gross-margin, node-mix, and guidance confirmation. For Lululemon (LULU), executive changes are only an option on better product execution; for Levi Strauss (LEVI), weaker DTC and a softer outlook make tariff-related earnings support less durable. Over the next 1–3 months, watch financing terms, rollout milestones, and forward guidance; over 6–18 months, capacity utilization and consumer sell-through are the real tests.

Key Decisions for Investors

• Avoid chasing WOLF's gap; reassess only after the loan's conditions, draw schedule, warrant mechanics, and liquidity runway are disclosed. Thesis is impaired if funding fails to close or subsequent guidance shows no operating improvement.
• Keep AVGO on a terms-driven watch, not an automatic short: verify who borrows, whether AVGO guarantees or advances funds, and the repayment protections before treating the arrangement as customer-financing exposure. Revisit if disclosures show limited recourse and firm purchase commitments.
• For APLD, wait for a signed hyperscaler contract with disclosed capacity, pricing, power sourcing, and funding before adding on the AI narrative. A self-build project without third-party commitments could validate demand while weakening the outsourced-capacity case.
• Prefer selective confirmation over headline trades: track HAE rollout/install progress and TSM margin and mix commentary; require improving North American product/sell-through evidence before buying LULU, and sustained DTC and outlook stabilization before reconsidering LEVI.